NCT01526980View on ClinicalTrials.gov

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period

DRUG

biphasic insulin aspart 70

Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period

DRUG

biphasic human insulin 30

Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period

Trial Locations (1)

Unknown

Novo Nordisk Investigational Site, Newcastle

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY